Literature DB >> 10326026

Immune responses limit adenovirally mediated gene expression in the adult mouse eye.

M B Reichel1, R R Ali, A J Thrasher, D M Hunt, S S Bhattacharya, D Baker.   

Abstract

In order to investigate the immunological consequences of gene transfer to the eye using viral vectors, adenovirus carrying a lacZ reporter gene (AV.LacZ) was injected either subretinally, subconjunctivally or into the anterior chamber of three groups of adult mice: immunocompetent or transiently immunosuppressed BALB/c mice and congenic immunodeficient nude mice. Adenovirally mediated lacZ expression persisted for approximately 3 weeks following injection of the vector into the anterior chamber, retina or extra ocular tissues of the conjuctiva of BALB/c mice. It appears that T cell-mediated immune responses limit the duration of AV-mediated ocular gene expression in adult mice since lacZ gene expression was detected for at least 15 weeks in T cell-deficient BALB/c nude mice, although the level of transgene expression decreased with time. Since intra-ocular AV-mediated gene expression was not significantly longer than extra-ocular expression, it appears that the eye is not normally immune-privileged with respect to viral vectors. Inflammatory cells were detected in the vitreous after anterior chamber injection and in the retina after subretinal injection of adenovirus. The presence of both CD4+ and CD8+ T cells was established by immunophenotyping. Reinjection of BALB/c mice resulted in rapid decline in reporter gene expression, but successful readministration was possible in the case of immunodeficient nude mice. However, after transient depletion of T cells, achieved by intraperitoneal injection of both CD8- and CD4-specific antibodies, the duration of expression in BALB/c mice was longer in the eye (at least 12 weeks, again with decrease in level over time), than in extra-ocular tissues (8 weeks) provided the animal was not reinjected with virus raising the possibility of partial ocular immune-privilege after transient immunosuppression.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10326026     DOI: 10.1038/sj.gt.3300691

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  16 in total

Review 1.  Molecular therapy in ocular wound healing.

Authors:  M F Cordeiro; G S Schultz; R R Ali; S S Bhattacharya; P T Khaw
Journal:  Br J Ophthalmol       Date:  1999-11       Impact factor: 4.638

Review 2.  Gene therapy using stem cells.

Authors:  Erin R Burnight; Luke A Wiley; Robert F Mullins; Edwin M Stone; Budd A Tucker
Journal:  Cold Spring Harb Perspect Med       Date:  2014-11-13       Impact factor: 6.915

Review 3.  Let There Be Light: Gene and Cell Therapy for Blindness.

Authors:  Deniz Dalkara; Olivier Goureau; Katia Marazova; José-Alain Sahel
Journal:  Hum Gene Ther       Date:  2016-02       Impact factor: 5.695

Review 4.  Gene therapy of inherited retinopathies: a long and successful road from viral vectors to patients.

Authors:  Pasqualina Colella; Alberto Auricchio
Journal:  Hum Gene Ther       Date:  2012-08       Impact factor: 5.695

5.  Gene transfer mediated by recombinant baculovirus into mouse eye.

Authors:  F Haeseleer; Y Imanishi; D A Saperstein; K Palczewski
Journal:  Invest Ophthalmol Vis Sci       Date:  2001-12       Impact factor: 4.799

6.  An immune response after intraocular administration of an adenoviral vector containing a beta galactosidase reporter gene slows retinal degeneration in the rd mouse.

Authors:  M B Reichel; J Bainbridge; D Baker; A J Thrasher; S S Bhattacharya; R R Ali
Journal:  Br J Ophthalmol       Date:  2001-03       Impact factor: 4.638

Review 7.  Retinal dystrophies and gene therapy.

Authors:  Venki Sundaram; Anthony T Moore; Robin R Ali; James W Bainbridge
Journal:  Eur J Pediatr       Date:  2011-11-15       Impact factor: 3.183

8.  Ex vivo adenovirus mediated gene transfection of human conjunctival epithelium.

Authors:  J Shen; N Taylor; L Duncan; I Kovesdi; J T Bruder; J V Forrester; A D Dick
Journal:  Br J Ophthalmol       Date:  2001-07       Impact factor: 4.638

Review 9.  Barriers for retinal gene therapy: separating fact from fiction.

Authors:  Rajendra Kumar-Singh
Journal:  Vision Res       Date:  2008-06-18       Impact factor: 1.886

10.  Down-regulation of inducible co-stimulator (ICOS) by intravitreal injection of small interfering RNA (siRNA) plasmid suppresses ongoing experimental autoimmune uveoretinitis in rats.

Authors:  Yongsheng Hou; Lin Xing; Shaoying Fu; Xiaoning Zhang; Jingjing Liu; Hongling Liu; Bingjie Lv; Hao Cui
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-01-06       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.